SCHEMBL1846246

SCHEMBL1846246

C/C(=C\CCl)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2504997 1.00
SCHEMBL7515150 0.78
SCHEMBL7515146 0.78
SCHEMBL11804103 0.78
SCHEMBL2769728 0.75
SCHEMBL9237609 0.75
SCHEMBL2769730 0.75
SCHEMBL3838092 0.73
SCHEMBL3838089 0.73
SCHEMBL8082421 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735624-B2 Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same INNATE PHARMA (FR) 2014-05-27 US disclosed
EP-2324040-B1 NOVEL POLYMORPHIC FORM OF CHDMAPP, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME INNATE PHARMA (FR) 2014-01-01 EP disclosed
US-20110245534-A1 NOVEL POLYMORPHIC FORM OF CHDMAPP, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME INNATE PHARMA (FR) 2011-10-06 US disclosed
EP-2324040-A1 NOVEL POLYMORPHIC FORM OF CHDMAPP, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Innate Pharma (FR) 2011-05-25 EP disclosed
US-20100291118-A1 Class of Gamma Delta T Cells Activators and Use Thereof INNATE PHARMA (FR) 2010-11-18 US disclosed
US-20100291118-A1 Class of Gamma Delta T Cells Activators and Use Thereof INNATE PHARMA (FR) 2010-11-18 US disclosed
US-20100291118-A1 Class of Gamma Delta T Cells Activators and Use Thereof INNATE PHARMA (FR) 2010-11-18 US disclosed
US-20100254940-A1 Compositions and Methods for Regulating an Immune Response in a Subject INNATE PHARMA, S.A. (FR) 2010-10-07 US disclosed
US-20100222306-A1 Class of Gamma Delta T Cells Activators and Use Thereof INNATE PHARMA, S.A. (FR) 2010-09-02 US disclosed
US-7767842-B2 Class of γδ T cells activators and use thereof INNATE PHARMA SA (FR) 2010-08-03 US disclosed
US-20070134273-A1 Composition and method for the treatment of carcinoma ROMAGNE FRANCOIS 2007-06-14 US disclosed
US-20070134273-A1 Composition and method for the treatment of carcinoma ROMAGNE FRANCOIS 2007-06-14 US disclosed
EP-1761278-A1 ADJUVANT COMPOSITION AND METHODS FOR ITS USE Innate Pharma (FR) 2007-03-14 EP disclosed
EP-1720567-A2 COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA Innate Pharma (FR) 2006-11-15 EP disclosed
WO-2006103568-A2 NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF INNATE PHARMA (FR) 2006-10-05 WO disclosed
US-20060194755-A1 Compositions and methods for regulating an immune response in a subject INNATE PHARMA, S.A.S. (FR) 2006-08-31 US disclosed
WO-2005102385-A1 ADJUVANT COMPOSITION AND METHODS FOR ITS USE INNATE PHARMA (FR) 2005-11-03 WO disclosed
EP-1569656-A2 PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE Innate Pharma (FR) 2005-09-07 EP disclosed
WO-2005077411-A2 COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA INNATE PHARMA (FR) 2005-08-25 WO disclosed
WO-2004050096-A2 PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE INNATE PHARMA (FR) 2004-06-17 WO disclosed